| Objective To study the effect of liraglutide on type 2 diabetic osteoporosis (T2DOP) rats based on the study of phosphatidylinositol-3 kinase/serine-threonine kinase (PI3K/Akt) pathway. Methods T2DOP rat model was established with high fat and high sugar intake, intraperitoneal injection of 30 mg/kg streptozotocin (STZ), and removal of the ovaries. The rats were randomly divided into model group, liraglutide group, and liraglutide+LY294002 group, and normal fed normal group, with 10 rats in each group. Body weight, fasting blood glucose, femoral tissue morphology, serum osteoprotegerin (OPG), nuclear factor KB receptor activator ligand (RANKL) levels, bone mineral density, femoral tissue phosphorylation-PI3K(p-PI3K), PI3K, phosphorylation-Akt (p-Akt), and Akt protein levels were compared. Results In the model group, body weight, FBG, and serum RANKL levels increased (P<0.05), serum OPG levels, femoral bone mineral density, p-PI3K/PI3K, and p-Akt/Akt protein levels decreased (P<0.05). In the liraglutide group, body weight, FBG, and serum RANKL levels decreased (P<0.05), and the serum OPG levels, femoral bone mineral density, and p-PI3K/PI3K, p-Akt/Akt protein levels increased (P<0.05). PI3K inhibitor LY294002 reversed the symptoms of liraglutide. Conclusion Liraglutide activates PI3K/Akt pathway to alleviate osteoporosis in T2DOP rats. |